Wan Bond: Summary table of non-operating capital usage and other related capital transactions for the first half year
Wan Bond: 2024 semi-annual financial report
Wan Bond: 2024 Semi-Annual Report
Wan Bond: 2024 Semi-Annual Report Summary
Wanbangde Pharmaceutical Holding Group: Announcement of the resolutions of the Ninth Meeting of the Ninth Board of Directors.
Wanbangde Pharmaceutical Holding Group: Announcement on the signing of the "Compensation Agreement for the Acquisition of Houses on State-owned Land" by the subsidiary.
Wanbangde Pharmaceutical Holding Group: Announcement of Annual Equity Distribution Implementation in 2023
Wanbangde Pharmaceutical Holding Group: Announcement on the subsidiary's products being certified as orphan drugs by the US FDA
Wanbangde Pharmaceutical Holding Group: Guohao Lawyer (Hangzhou) Firm's Special Inspection Opinions on the Company's Actual Controller's Increased Shareholding
Wanbangde Pharmaceutical Holding Group: Announcement on the implementation results of the company's actual controller's plan to increase the company's share holdings
Wanbangde Pharmaceutical Holding Group: Wan Bond's 2023 Annual General Meeting of Shareholders Legal Opinion
Wanbangde Pharmaceutical Holding Group: Announcement of Resolutions of the 2023 Annual General Meeting of Shareholders
Wanbangde Pharmaceutical Holding Group: Notice on convening the 2023 Annual General Meeting of Shareholders (after correction)
Wanbangde Pharmaceutical Holding Group: Corrective Notice Concerning the Notice of Convening the 2023 Annual General Meeting of Shareholders
Wanbangde Pharmaceutical Holding Group: 0020.82 million Bond Investor Relations Management Information 20240510
Wanbangde Pharmaceutical Holding Group: Announcement on the progress of the company's actual controller's plan to increase the company's shares for more than half of the time
Wanbangde Pharmaceutical Holding Group: Northeast Securities 2023 Continued Supervision Opinions and Continued Supervision Summary Report on Wanbond's Issuance of Shares to Purchase Assets and Related Transactions
Wanbangde Pharmaceutical Holding Group: Notice on subsidiary products receiving US FDA drug certification for rare pediatric diseases
Wanbangde Pharmaceutical Holding Group: Announcement on holding the 2023 online results briefing
Wanbangde Pharmaceutical Holding Group: Announcement of Board Resolutions
No Data